Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 3, 2017

View Archived Issues

Orexo signs asset purchase agreement with Gesynta for OX-MPI program

Nohla Therapeutics obtains CIRM grant to support development of cell therapy for AML

MicroRNA expression profile identified for kidney antibody-mediated rejection

Regeneron Pharmaceuticals establishes agreement with BARDA

Opiant and Titan to develop product for opioid use disorder

Seres Therapeutics reports topline results from phase Ib study of SER-287 in ulcerative colitis

First-in-human study shows utility of [11C]-preladenant in imaging brain adenosine receptors

FDA grants orphan drug designation to Stealth BioTherapeutics' elamipretide for PMM

Janssen applies for U.S. approval of Invokana for CV events in patients with type 2 diabetes

FDA accepts Avycaz sNDA for priority review

Dipeptidyl peptidase 1 inhibitor AZD-7986 affects neutrophil serine proteases in humans

FDA not to hold committee meeting to discuss Rigel's NDA for fostamatinib

Vanderbilt University describes new Mcl-1 inhibitors

Ancureall Biomedical Technology identifies novel FLT3-ITD inhibitors

Bayer divulges novel PGF receptor antagonists

Novel PPAR-gamma agonists developed at Zhejiang Xuchen Pharmaceutical Technology

Exerkine creates novel neuropeptide gene therapy

KSQ Therapeutics secures USD 76 million to support CRISPRomics-powered drug discovery

bluebird bio initiates phase I study of bb-21217 in multiple myeloma

Astellas initiates phase I study of immune checkpoint inhibitor ASP-8374 in solid tumors

Novartis studies LLG-783 in patients with peripheral artery disease and intermittent claudication

Aptevo completes sale of three hyperimmune products to Saol Therapeutics

Topline phase II/III results do not support continued development of trigriluzole for SCA

CYP3A4 interactions with sodium channel blocker BIIB-074 studied in healthy subjects

FDA awards breakthrough therapy designation to Adcetris for Hodgkin's lymphoma

Sato and Eisai agree to copromote fosravuconazole in Japan

First patient dosed in phase I study of Pieris Pharmaceuticals' PRS-343

Takeda reports results from Japanese phase III trial of relugolix in uterine fibroids

U.S. BARDA announces agreements to purchase four Ebola countermeasures